Pharmaceuticals

Global Neurodegenerative Disease Market Projected for Strong Growth, Reaching $88.5 Billion by 2030 at 9% CAGR

March 23, 2026March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Neurodegenerative Disease Market By 2030 Starting From Its 2026 Size?

The neurodegenerative disease market size has demonstrated significant expansion in recent years. This market is projected to grow from $57.23 billion in 2025 to $62.59 billion in 2026, at a compound annual growth rate (CAGR) of 9.4%. The historical period’s growth can be attributed to a limited understanding of disease pathology, a reliance on conventional symptomatic treatments, an increasing aging population, improvements in healthcare infrastructure for neurology, and the restricted availability of advanced diagnostic tools.

The neurodegenerative disease market size is anticipated to undergo significant expansion in the coming years. It is projected to reach $88.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.0%. The growth expected in the forecast period can be attributed to advancements in gene and cell therapy, increasing research and development in novel neuroprotective drugs, the expansion of clinical trial networks, the integration of AI for early diagnosis and patient monitoring, and the rising adoption of personalized medicine approaches. Major trends for the forecast period include the increasing prevalence of neurodegenerative disorders, a rise in investment in drug development and clinical trials, the implementation of targeted and personalized therapies, enhanced awareness and early diagnosis programs, and the expansion of home-based and outpatient care solutions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24618&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Neurodegenerative Disease Market?

An expansion in research and clinical trials is expected to propel the growth of the neurodegenerative disease market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices. The increase in research and clinical trials is primarily driven by the rising demand for new treatments to address evolving healthcare needs and improve patient outcomes. These trials support neurodegenerative disease research by providing critical data on the safety and effectiveness of new treatments, helping to advance therapeutic development and improve patient outcomes. For instance, in December 2024, according to a report published by the Association of the British Pharmaceutical Industry (ABPI), a UK-based association, the number of UK industry clinical trials initiated rose by 3.7% in 2023 compared to 2022. Therefore, the increase in research and clinical trials is expected to propel the growth of the neurodegenerative disease market.

Which Segment Categories Define The Neurodegenerative Disease Market?

The neurodegenerative disease market covered in this report is segmented –

1) By Disease Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis

2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types

3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospital, Retail, Online

Subsegments:

1) By Parkinson’s Disease: Idiopathic Parkinson’s Disease, Familial Parkinson’s Disease, Early-Onset Parkinson’s Disease, Parkinsonism

2) By Alzheimer’s Disease: Early-Onset Alzheimer’s Disease, Late-Onset Alzheimer’s Disease, Familial Alzheimer’s Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype

3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)

4) By Huntington’s Disease: Adult-Onset Huntington’s Disease, Juvenile Huntington’s Disease

5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)

What Major Market Trends Are Driving Changes In The Neurodegenerative Disease Market?

Major companies operating in the neurodegenerative disease market are dedicating efforts to developing innovative products, such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, with the aim of improving treatment precision, enhancing disease-modifying effects, and increasing patient quality of life. These next-generation adaptive deep brain stimulation (aDBS) systems are advanced neurostimulation devices engineered to deliver real-time, personalized treatment for Parkinson’s disease by dynamically adjusting stimulation parameters based on neural feedback, thereby optimizing therapeutic effects and minimizing side effects for improved patient outcomes. For instance, in February 2025, Medtronic, a US-based medical technology company, obtained approval from the U.S. Food and Drug Administration (USFDA) for the world’s first adaptive deep brain stimulation (aDBS) system designed for Parkinson’s disease. This authorization specifically concerns the premarket approval (PMA) application for the Percept RC neurostimulator with BrainSense technology, which automatically modifies therapy in response to a patient’s brain signals. The system has undergone clinical validation, demonstrating its ability to provide symptom relief for advanced Parkinson’s disease patients, and signifies a substantial stride forward in personalized neuromodulation therapies.

Who Are The Top Companies Competing In The Neurodegenerative Disease Market?

Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

Read the full neurodegenerative disease market report here:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disease-global-market-report

Which Regions Are Projected To Dominate The Neurodegenerative Disease Market In The Coming Years?

North America was the largest region in the neurodegenerative disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurodegenerative Disease Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24618&type=smp

Browse Through More Reports Similar to the Global Neurodegenerative Disease Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Degenerative Disc Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/degenerative-disc-disease-treatment-global-market-report

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795